Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OMACETAXINE MEPESUCCINATE: 957 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
957
Total FAERS Reports
94 (9.8%)
Deaths Reported
316
Hospitalizations
957
As Primary/Secondary Suspect
25
Life-Threatening
10
Disabilities
Oct 26, 2012
FDA Approved
Discontinued
Status

FDA Application: 203585 ·

Patent Expires: Oct 26, 2026 · First Report: 2007 · Latest Report: 20250923

What Are the Most Common OMACETAXINE MEPESUCCINATE Side Effects?

#1 Most Reported
Myelosuppression
178 reports (18.6%)
#2 Most Reported
Nausea
154 reports (16.1%)
#3 Most Reported
Platelet count decreased
105 reports (11.0%)

All OMACETAXINE MEPESUCCINATE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Myelosuppression 178 18.6% 7 94
Nausea 154 16.1% 7 43
Platelet count decreased 105 11.0% 5 43
Fatigue 76 7.9% 3 19
Diarrhoea 73 7.6% 4 17
White blood cell count decreased 71 7.4% 3 34
Vomiting 63 6.6% 4 21
Injection site erythema 61 6.4% 1 9
Death 60 6.3% 60 24
Asthenia 57 6.0% 6 22
Pyrexia 56 5.9% 4 36
Headache 47 4.9% 2 7
Neutropenia 43 4.5% 3 16
Haemoglobin decreased 40 4.2% 4 23
Off label use 40 4.2% 4 10
Drug ineffective 35 3.7% 4 4
Infection 35 3.7% 3 7
Alopecia 32 3.3% 0 7
Blood count abnormal 32 3.3% 1 10
Neutrophil count decreased 32 3.3% 0 19

Who Reports OMACETAXINE MEPESUCCINATE Side Effects? Age & Gender Data

Gender: 50.0% female, 50.0% male. Average age: 53.3 years. Most reports from: US. View detailed demographics →

Is OMACETAXINE MEPESUCCINATE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2007 1 0 1
2011 1 0 1
2013 1 0 0
2014 23 0 8
2015 63 3 16
2016 74 9 29
2017 62 9 30
2018 38 3 21
2019 33 9 14
2020 31 0 13
2021 29 0 14
2022 31 0 13
2023 35 0 18
2024 69 1 49
2025 36 0 29

View full timeline →

What Is OMACETAXINE MEPESUCCINATE Used For?

IndicationReports
Chronic myeloid leukaemia 500
Acute myeloid leukaemia 193
Chemotherapy 38
Product used for unknown indication 29
Myelodysplastic syndrome 19
Acute leukaemia 17
Leukaemia 15
Acute promyelocytic leukaemia 13
T-cell type acute leukaemia 13
Philadelphia chromosome positive 10

OMACETAXINE MEPESUCCINATE vs Alternatives: Which Is Safer?

OMACETAXINE MEPESUCCINATE vs OMADACYCLINE OMACETAXINE MEPESUCCINATE vs OMALIZUMAB OMACETAXINE MEPESUCCINATE vs OMAVELOXOLONE OMACETAXINE MEPESUCCINATE vs OMBITASVIR OMACETAXINE MEPESUCCINATE vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMACETAXINE MEPESUCCINATE vs OMEGA-3-ACID ETHYL ESTERS OMACETAXINE MEPESUCCINATE vs OMEGA-3-CARBOXYLIC ACIDS OMACETAXINE MEPESUCCINATE vs OMEGA-3 FATTY ACIDS OMACETAXINE MEPESUCCINATE vs OMEPRAZOLE OMACETAXINE MEPESUCCINATE vs OMEPRAZOLE\SODIUM BICARBONATE

Official FDA Label for OMACETAXINE MEPESUCCINATE

Official prescribing information from the FDA-approved drug label.